January 4, 2008 — According to a new study published in the January 3 issue of the New England Journal of Medicine, capecitabine (Xeloda, Roche) and oxaliplatin (Eloxatin, Sanofi-Aventis) appear to be ...
Chemoradiation is now used more commonly for gastric cancer following publication of the US Intergroup trial results that demonstrate an advantage to adjuvant postoperative chemoradiotherapy. However, ...
Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Motesanib (AMG-706) in Combination With Paclitaxel and Carboplatin in East Asian Patients With Advanced Nonsquamous Non–Small-Cell Lung ...
Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients (pts) with untreated advanced gastric cancer (AGC). Background: Gastric Cancer ...
The superiority of docetaxel based triplet therapy over standard care in patients with resectable esophago-gastric cancer has been confirmed in late-breaking results from the FLOT4 trial presented at ...
Irinotecan, mitomycin and cisplatin all demonstrate activity in gastro-oesophageal cancers. This novel combination was administered to outpatients with previously untreated inoperable ...
Another alteration was substituting capecitabine, the oral prodrug of 5-FU, for the latter, along with a substitution of cisplatin with oxaliplatin, since the latter is much less emetogenic and toxic ...
The Appraisal Committee considered evidence submitted by the manufacturer of capecitabine and a review of this submission by the Evidence Review Group (ERG). The REAL-2 trial was an open-label UK ...
LUGANO-MADRID, 8 September, 2017 - The superiority of docetaxel based triplet therapy over standard care in patients with resectable oesophago-gastric cancer has been confirmed in late-breaking ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results